Drug Type Small molecule drug |
Synonyms HS 10370, HS-10370, HS10370 |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 03 Jun 2022 | |
KRAS G12C mutation Solid Tumors | Phase 1 | CN | 31 Oct 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 26 Aug 2024 | |
KRAS G12C mutant Non-small Cell Lung Cancer | Phase 1 | CN | 27 May 2022 |
Phase 1 | KRAS G12C mutation Solid Tumors KRAS G12C | 55 | uhzofphnsq(tcztcqdlcx) = ttztyfiaje eywxbybupq (quentptwqo ) View more | Positive | 05 Apr 2024 |